Exploratory biomarker analysis of the phase 2 MITO END 3 trial in advanced endometrial cancer: of 102 sequenced tumours, 5 were HRDsig-positive and 10 gLOH-high, mostly endometrioid with TP53 mutations; none were MSI-high.
RCTn = 102
Bartoletti et al. Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial